Omixon is a global biotechnology company that commercializes disruptive innovations specializing in targeted applications for Next Generation Sequencing (NGS). The Omixon Holotype HLA™ product combines a targeted HLA Assay and the Omixon HLA Twin™ software to deliver the most accurate high-resolution HLA genotyping available. Omixon maintains an active grant-funded research program and assists scientists and clinicians to analyze the most challenging genomic regions including HLA, KIR and ABO.
It’s already the middle of January, so before the new year steadily sets in, we’d like to have a quick look back on the route we just came, not long ago. Omixon had an amazing and very successful 2014. We launched our …more
Cancer has become one of the biggest killers in the western world. High profile campaigns to tackle breast cancer and other common types have ensured that it is also one of the biggest businesses in modern medicine. To fight a …more